1. ALLA AKTIER
  2. NYHETER
  3. VÄSTRA HAMNEN CORP. FINANCE

Västra Hamnen Corp. Finance

Nyheter Västra Hamnen Corp. Finance Nyheter alla bolag

CombiGene: Advancements according to plan

  • New agreement with Spark Therapeutics regarding CG01
  • Activities advances the COZY programme
  • We keep our fair value of SEK 12.19 per share

During CombiGene's Q2, the most significant event was the licensing agreement with Spark Therapeutics, which formally returns CG01 to CombiGene. The company will gain access to study data, while Spark will receive single-digit royalties on an approved product. Progress has also been made within the COZY program, including a study confirming that the target protein is expressed in human peripheral neuronal tissue. Financially, the company reported a cash flow of MSEK -17.8 for Q2 and had cash holdings of MSEK 83.5 at the end of the period. We maintain our fair value of SEK 12.19 per share.

The full report is available here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Datum 2024-08-29, kl 14:00
Källa MFN
Affiliate
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet